RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer

Impressive overall response rate with avutometinib-defactinib in RAMP 201 trial

Related Keywords

United States ,Memorial Sloan Kettering Cancer Center ,New York ,South Korea ,Seoul ,Soult Ukpyolsi ,American ,Racheln Grisham , ,Pinternational Gynecologic Cancer Society ,American Society Of Clinical Oncology ,New York City ,Clinical Oncology ,